Health Condition 1: B359- Dermatophytosis, unspecified
Conditions
Interventions
Intervention1: Super Bioavailable Itraconazole: Super Bioavailable Itraconazole at a dose of 50 mg twice daily given orally for a duration of 4 to 6 weeks in case of dermatophytic infections with regu
Sponsors
AIIMS Hospital Raebareli
Eligibility
Inclusion criteria
Inclusion criteria: ALL patients with dermatophytic infections except fungal infections of hair and nail Body surface area >20% positive koh mount
Exclusion criteria
Exclusion criteria: Pregnant and lactating females pts with liver dysfunction Pt already taken any other antifungal drug/ steroids ( apart from topical agents) 2 weeks prior Children Pts with congestive heat failure and pts who develop hypersensitivity reaction to itraconazole or any of its component
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete cure achieved at the end of 4 weeks or at the end of 6 weeks decided by both: CLINICAL CRITERIA: Relief in itching Healing of plaques Healthy normal skin LABORATORICAL CRITERIA: Negative KOH mount for fungal infectionTimepoint: 4 WEEKS 6 WEEKS | — |
Secondary
| Measure | Time frame |
|---|---|
| Any other adverse effects experienced by patientTimepoint: 4 WEEKS 6 WEEKS;Safety of Conventional Itraconazole vs Super Bioavailable Itraconazole tested by: Liver Function Tests at 4th & 6th week. Timepoint: 4 WEEKS 6 WEEKS | — |
Countries
India
Contacts
Public ContactDr SAKSHI
AIIMS Raebareli
Outcome results
None listed